[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS62676B1 - Formulacije enzalutamida - Google Patents

Formulacije enzalutamida

Info

Publication number
RS62676B1
RS62676B1 RS20211117A RSP20211117A RS62676B1 RS 62676 B1 RS62676 B1 RS 62676B1 RS 20211117 A RS20211117 A RS 20211117A RS P20211117 A RSP20211117 A RS P20211117A RS 62676 B1 RS62676 B1 RS 62676B1
Authority
RS
Serbia
Prior art keywords
enzalutamide
formulations
Prior art date
Application number
RS20211117A
Other languages
English (en)
Inventor
Douglas Alan Lorenz
Sanjay Konagurthu
Randy J Wald
Jason A Everett
Sheila Matz
Yuuki Takaishi
Toshiro Sakai
Ryousuke Irie
Shinsuke Oba
Hiroyasu Toyota
Koji Nishimura
Atsushi Kanbayashi
Original Assignee
Medivation Prostate Therapeutics Llc
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62676(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc, Astellas Pharma Inc filed Critical Medivation Prostate Therapeutics Llc
Publication of RS62676B1 publication Critical patent/RS62676B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20211117A 2012-09-11 2013-09-11 Formulacije enzalutamida RS62676B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699351P 2012-09-11 2012-09-11
EP20177837.0A EP3725778B1 (en) 2012-09-11 2013-09-11 Formulations of enzalutamide

Publications (1)

Publication Number Publication Date
RS62676B1 true RS62676B1 (sr) 2021-12-31

Family

ID=49231627

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211117A RS62676B1 (sr) 2012-09-11 2013-09-11 Formulacije enzalutamida

Country Status (28)

Country Link
US (9) US20140100256A1 (sr)
EP (6) EP3971167A1 (sr)
JP (5) JP6404217B2 (sr)
KR (1) KR102225416B1 (sr)
CN (2) CN109897004A (sr)
AU (2) AU2013315619B2 (sr)
BR (1) BR112015005432B1 (sr)
CA (1) CA2884795C (sr)
CY (1) CY1124729T1 (sr)
DK (1) DK3725778T3 (sr)
EA (2) EA033374B9 (sr)
ES (1) ES2892029T3 (sr)
HK (1) HK1212701A1 (sr)
HR (1) HRP20211423T1 (sr)
HU (1) HUE057701T2 (sr)
IL (1) IL237604B (sr)
IN (1) IN2015DN02875A (sr)
LT (1) LT3725778T (sr)
MX (3) MX363974B (sr)
PH (1) PH12015500525A1 (sr)
PL (1) PL3725778T3 (sr)
PT (1) PT3725778T (sr)
RS (1) RS62676B1 (sr)
SI (1) SI3725778T1 (sr)
TW (1) TWI673051B (sr)
UA (1) UA117353C2 (sr)
WO (1) WO2014043208A1 (sr)
ZA (1) ZA201501847B (sr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013315619B2 (en) 2012-09-11 2018-02-08 Astellas Pharma Inc. Formulations of enzalutamide
UA124967C2 (uk) 2012-09-26 2021-12-22 Араґон Фармасьютікалз, Інк. Антиандрогени для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
MY189663A (en) * 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CN106102716A (zh) * 2014-02-05 2016-11-09 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
CR20170218A (es) 2014-12-05 2017-08-30 Aragon Pharmaceuticals Inc Composiciones anticancerígenas
MA41108B1 (fr) * 2014-12-05 2021-03-31 Aragon Pharmaceuticals Inc Compositions anticancéreuses
US20180022819A1 (en) * 2015-02-11 2018-01-25 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
CN104546714A (zh) * 2015-02-11 2015-04-29 江苏慧博生物科技有限公司 一种恩杂鲁胺胶束制剂及其制备方法
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
WO2017027665A1 (en) 2015-08-12 2017-02-16 Medivation Prostate Therapeutics, Inc. Treatment of cancer using a combination of enzalutamide and a cyp3a4 inducer
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
US20180344649A1 (en) 2015-09-29 2018-12-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
EP3487497B1 (en) 2016-07-21 2021-09-08 Hadasit Medical Research Services and Development Ltd. Combinations comprising ar antagonists or inhibitors for use in treating glioblastoma
WO2018037310A1 (en) 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
ES2886842T3 (es) * 2017-04-13 2021-12-21 Jean Paul Remon Composiciones a base de xanthohumol
WO2018199282A1 (ja) 2017-04-28 2018-11-01 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
RU2020109948A (ru) * 2017-08-08 2021-09-10 Др. Редди'З Лабораториз Лимитед Экструдированные композиции энзалутамида
SG11202003402QA (en) 2017-10-16 2020-05-28 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
CA3094591C (en) 2018-04-06 2024-03-26 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
WO2020122244A1 (ja) * 2018-12-14 2020-06-18 富士フイルム株式会社 錠剤及びその製造方法
CN109432016B (zh) * 2018-12-26 2021-03-02 广州中医药大学(广州中医药研究院) 一种恩杂鲁胺的三元固体制剂及其制备方法
WO2020144649A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising enzalutamide dispersed in apple sauce
MX2021009184A (es) 2019-01-30 2021-11-12 Janssen Pharmaceutica Nv Métodos para tratar cáncer de próstata basado en subtipos moleculares.
KR20210153038A (ko) 2019-01-30 2021-12-16 아라곤 파마슈티컬스, 인코포레이티드 전이성 거세-민감성 전립선암의 치료를 위한 항안드로겐
US20220133638A1 (en) 2019-05-16 2022-05-05 Leon-Nanodrugs Gmbh Method for producing nanoparticles
CA3141534A1 (en) 2019-05-23 2020-11-26 Helm Ag Nanoparticles comprising enzalutamide
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3990435A1 (en) 2019-06-27 2022-05-04 Synthon B.V. Process for preparation of enzalutamide
EP4031109A1 (en) * 2019-09-18 2022-07-27 Bristol-Myers Squibb Company Extended release dosage forms for tyk2 inhibitors
CA3149182A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
CA3152909A1 (en) 2019-10-03 2021-04-08 Synthon Bv Pharmaceutical composition comprising enzalutamide
JP2023500935A (ja) 2019-11-04 2023-01-11 アラゴン ファーマシューティカルズ，インコーポレイテッド 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法
CN118251213A (zh) * 2022-01-19 2024-06-25 四川科伦药物研究院有限公司 固体分散体及其制备方法和包含其的药物组合物
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
WO2023244617A1 (en) * 2022-06-13 2023-12-21 Virginia Polytechnic Institute And State University Amphiphilic cellulose derivatives, methods of making, and uses thereof
TW202416960A (zh) * 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
CN115887395A (zh) * 2022-11-18 2023-04-04 上海药坦药物研究开发有限公司 恩杂鲁胺固体分散体制剂及其制备方法和应用
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
WO2024153733A1 (en) 2023-01-18 2024-07-25 Helm Ag Crystalline nanoparticles comprising enzalutamide
WO2024189186A1 (en) 2023-03-16 2024-09-19 Bayer Consumer Care Ag Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer
CN118001243B (zh) * 2024-01-31 2024-10-22 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
EP1745774A3 (en) 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
IN191496B (sr) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
CA2439366A1 (en) 2001-02-27 2002-09-06 Julie Cahill Pharmaceutical formulation comprising bicalutamide
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
SE0103839D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
CA2474958A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
AU2003229912A1 (en) 2002-04-18 2003-11-03 Avecia Limited Prepation of a conjugated molecule and materials for use therein
JP4249950B2 (ja) 2002-06-28 2009-04-08 富士フイルム株式会社 紙管切断装置及び紙管切断方法
US20050020675A1 (en) * 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
US7611630B2 (en) 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR20240148945A (ko) * 2005-05-13 2024-10-11 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
CA2608952A1 (en) 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
CN101277682B (zh) 2005-07-28 2015-07-29 Isp投资有限公司 无定形依发韦仑及其生产
PT2656842T (pt) 2006-03-27 2016-10-04 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US20100151035A1 (en) 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
AU2009224418B2 (en) * 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
EP2414356B1 (en) 2009-04-03 2015-09-02 F.Hoffmann-La Roche Ag Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
SI3329775T1 (sl) * 2010-02-24 2021-09-30 Medivation Prostate Therapeutics Llc Procesi za sintezo spojin diariltiohidantoina in diarilhidantoina
CN103118681B (zh) * 2010-03-10 2015-02-18 艾伯维巴哈马有限公司 固体组合物
SG10201610249TA (en) 2012-06-07 2017-02-27 Aragon Pharmaceuticals Inc Crystalline forms of an androgen receptor modulator
CN104641505B (zh) * 2012-08-10 2018-06-19 凯萨股份有限公司 用于ehf通信的电介质耦合系统
WO2014042945A1 (en) 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
BR112015005404A2 (pt) 2012-09-11 2017-08-22 Dr Reddys Laboratories Ltd Formas polimórficas de enzalutamida e sua preparação
AU2013315619B2 (en) 2012-09-11 2018-02-08 Astellas Pharma Inc. Formulations of enzalutamide
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
WO2018199282A1 (ja) 2017-04-28 2018-11-01 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
US20190208236A1 (en) 2018-01-02 2019-07-04 Source Digital, Inc. Coordinates as ancillary data
CA3152909A1 (en) 2019-10-03 2021-04-08 Synthon Bv Pharmaceutical composition comprising enzalutamide

Also Published As

Publication number Publication date
US20230122911A1 (en) 2023-04-20
ZA201501847B (en) 2016-01-27
MX2015003140A (es) 2015-12-16
JP2018087206A (ja) 2018-06-07
CY1124729T1 (el) 2022-07-22
EP3725778B1 (en) 2021-08-18
EP4450130A2 (en) 2024-10-23
EA201991484A1 (ru) 2019-11-29
PH12015500525A1 (en) 2015-05-04
CA2884795A1 (en) 2014-03-20
HK1212701A1 (zh) 2016-06-17
EP3971167A1 (en) 2022-03-23
MX363974B (es) 2019-04-10
US20140179749A1 (en) 2014-06-26
DK3725778T3 (da) 2021-09-20
PL3725778T3 (pl) 2021-12-20
US20190209476A1 (en) 2019-07-11
US20230210778A1 (en) 2023-07-06
MX2021000007A (es) 2021-03-09
EP4169908A1 (en) 2023-04-26
UA117353C2 (uk) 2018-07-25
IL237604A0 (en) 2015-04-30
BR112015005432A2 (sr) 2017-09-05
EP2895463A1 (en) 2015-07-22
JP2016204392A (ja) 2016-12-08
JP2019194262A (ja) 2019-11-07
US20170027910A1 (en) 2017-02-02
TW201427659A (zh) 2014-07-16
EA201500314A1 (ru) 2015-12-30
SI3725778T1 (sl) 2022-02-28
BR112015005432B1 (pt) 2023-04-18
CN109897004A (zh) 2019-06-18
WO2014043208A1 (en) 2014-03-20
IN2015DN02875A (sr) 2015-09-11
EP4324527A3 (en) 2024-04-24
AU2013315619B2 (en) 2018-02-08
ES2892029T3 (es) 2022-02-01
HUE057701T2 (hu) 2022-05-28
US20170224624A1 (en) 2017-08-10
KR20150082203A (ko) 2015-07-15
JP2021178871A (ja) 2021-11-18
CN105358535A (zh) 2016-02-24
US11839689B2 (en) 2023-12-12
KR102225416B1 (ko) 2021-03-09
EP3725778A1 (en) 2020-10-21
JP6404217B2 (ja) 2018-10-10
PT3725778T (pt) 2021-09-22
EA033374B9 (ru) 2019-12-18
LT3725778T (lt) 2021-12-27
CN105358535B (zh) 2019-01-04
MX2019003984A (es) 2019-08-12
AU2018200316A1 (en) 2018-02-08
JP2015527411A (ja) 2015-09-17
CA2884795C (en) 2023-10-17
US20140100256A1 (en) 2014-04-10
AU2013315619A1 (en) 2015-04-30
EA033374B1 (ru) 2019-10-31
EP4324527A2 (en) 2024-02-21
US20200060976A1 (en) 2020-02-27
US20140378517A1 (en) 2014-12-25
IL237604B (en) 2021-07-29
HRP20211423T1 (hr) 2022-01-21
JP6932746B2 (ja) 2021-09-08
TWI673051B (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
HK1212701A1 (zh) 恩雜魯胺製劑
EP2814487A4 (en) BENDAMUSTIN FORMULATIONS
HK1210914A1 (en) Formulations of clomazone
ZA201406082B (en) Use of ccr3-inhibitors
RS65177B1 (sr) Formulacije bendamustina
HK1208173A1 (en) Bromocriptine formulations
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
HK1202445A1 (en) New formulation
ZA201306000B (en) Stable formulation
IL236312A0 (en) Preparation of 18f-flucyclobin
EP2881113A4 (en) NEW APPLICATION OF POGOSTONE
PT2908835T (pt) Formulações estáveis
EP2892529A4 (en) USES OF (-) - PERHEXILINE
IL217807A0 (en) Therapeutic compositions
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
PL2908859T3 (pl) Formulacje arypiprazolu
IL233879A0 (en) Dry powdered dnase i preparations
GB201206178D0 (en) Formulations
HUE036665T2 (hu) Dihidro-pirido-oxazin származék szilárd formái
TWM433525U (en) Structure of calorifier
GB201211247D0 (en) Improved formulation
GB201216165D0 (en) Virtues iBrush